CEL-SCI Corp.’s (NYSE MKT: CVM) body of work with the human immune system is one of perseverance and a passion for survival despite odds that would make the vast majority of biotech companies fold their tents and choose easier endeavors. Faced with trending downturns in the biotech sector, limited funding, and an arduous clinical trial process connected with the development of its investigational therapy for advanced primary head and neck cancer, the company’s mission is now well within sight. CVM’s lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now enrolling patients for a global Phase III trial.
The inception of CVM’s journey began at the Max Planck Institute in Germany in the late 1970s and has been fueled with science and research supporting the theory that the immune system is inherently a cancer fighter. Company founder, Maximilian de Clara, believed strongly that the immune system is pivotal in fighting this disease, but he did not have the technology to transition his concept to product. Brushing off discouragement, Maximilian funded the early Multikine research at the Max Plank Institute in 1978, founded CEL-SCI around the idea of Multikine in 1983, and later took CVM public.
The company’s mission is to improve the treatment of cancer and other diseases by utilizing the immune system. CEL-SCI Corp. aims to create shareholder value by developing unique therapies that address medical needs that are commonly unmet. The company is dedicated to developing its therapies using a scientific and data-driven approach.
CVM’s undying spirit aims to be science-based and data driven – taking no shortcuts on its road to drug development. The company is steadfast in its ethics and integrity while being economical in its daily approach to creating shareholder value.
Multikine is the registered trademark under which CEL-SCI has its investigational therapy. The proprietary name is subject to FDA review in connection with additional, anticipated regulatory submission for approval measures. Multikine has not been licensed or approved for sale by the FDA or any other regulatory agency at this time and its safety or efficacy has not been established for any use. Further research is required, and early-phase clinical trial results must be confirmed in Phase III clinical trials, which are currently underway. CEL-SCI Corporation is headquartered in Vienna, Virginia.
For more information on this company visit http://www.cel-sci.com